Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Rilpivirine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 2,527Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Somerset’s Generics Rilpivirine Receives Tentative Approval in US
    Somerset’s Generics Rilpivirine Receives Tentative Approval in US

    20 Aug 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218798

    FDA
    20 Aug 2025
    Share Share
    Viatris’ Emtricitabine Rilpivirine Receives Approval In Europe
    Viatris’ Emtricitabine Rilpivirine Receives Approval In Europe

    19 Aug 2025

    // EMA

    https://www.ema.europa.eu/en/documents/overview/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris-epar-medicine-overview_en.pdf

    EMA
    19 Aug 2025
    Share Share
    89% of HIV Patients Choose ViiV’s Long-Acting Injection
    89% of HIV Patients Choose ViiV’s Long-Acting Injection

    14 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250714839509/en/ViiV-Healthcare-data-show-89-of-treatment-nave-people-with-HIV-choose-to-switch-to-long-acting-injectable-Vocabria-Rekambys-from-daily-pills-after-achieving-rapid-viral-suppression

    BUSINESSWIRE
    14 Jul 2025
    Share Share
    U.S. FDA Approves EDURANT® PED (rilpivirine) for Certain Pediatric Patients Living with HIV-1
    U.S. FDA Approves EDURANT® PED (rilpivirine) for Certain Pediatric Patients Living with HIV-1

    19 Mar 2024

    // PFRESS RELEASE

    https://www.jnj.com/media-center/press-releases/u-s-fda-approves-edurant-ped-rilpivirine-for-certain-pediatric-patients-living-with-hiv-1

    PFRESS RELEASE
    19 Mar 2024
    Share Share
    ViiV Healthcare Announces Data at CROI Indicating Efficacy of Cabenuva
    ViiV Healthcare Announces Data at CROI Indicating Efficacy of Cabenuva

    06 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240305691015/en

    BUSINESSWIRE
    06 Mar 2024
    Share Share
    GSK's injectable HIV drug shows promise over daily pills
    GSK's injectable HIV drug shows promise over daily pills

    22 Feb 2024

    // PRESS RELEASE

    https://www.gsk.com/en-gb/media/press-releases/latitude-phase-iii-interim-trial-data-indicates-cabenuva-has-superior-efficacy-compared-to-daily-therapy/

    PRESS RELEASE
    22 Feb 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.